Unlock the Latest in Cancer Treatment: Sanofi and Innate Pharma’s Sar443579/IPH6101 Breakthrough
Innate Pharma has announced the initiation of the Phase 2 dose expansion portion of a clinical trial sponsored by...
New Findings on Alzheimer’s Drug Daxxify Unveiled at Neurology Conference
Revance Therapeutics announced two poster presentations showcasing the efficacy and performance of DAXXIFY® for the treatment of cervical dystonia....
CND Life Sciences’ Skin Biopsy Tool: A Breakthrough for Parkinson’s Diagnosis
The Synuclein-One Study has successfully detected P-SYN in cutaneous nerve fibers of patients with dementia with Lewy bodies (DLB)...
Mei Pharma’s Bold Move to Advance Cancer Treatment with Voruciclib and ME-344
MEI Pharma’s Board of Directors has unanimously adopted a strategic plan focused on prioritizing the clinical development of voruciclib,...
Unveiling the Power of RF Energy: Groundbreaking Advance in Glioblastoma Treatment
EMulate Therapeutics has announced the publication of a peer-reviewed study demonstrating its ulRFE device’s efficacy in a murine glioblastoma...
DeepCure Closes $24M Funding Round Led by IAG Capital Partners
DeepCure, a pioneer in AI-powered small molecule drug discovery, has closed a $24.6 million Series A-1 financing round led...
Boundless Bio Announces First Patient Dosed in Phase 1/2 Trial for Cancer Patients
Boundless Bio has initiated patient enrollment in a Phase 1/2 clinical trial (STARMAP) to investigate BBI-825, a novel therapy...
EPiENDO Reports Results for Lead Asset, EP395, in COPD
EpiEndo Pharmaceuticals has successfully concluded its Phase 2A clinical trial evaluating EP395, a novel oral therapeutic for Chronic Obstructive...
Amra Medical’s Breakthrough Fat Z-Score Biomarkers Unlock the Power of Tirzepatide Treatment
Recent research from AMRA Medical and collaborators has highlighted the impact of tirzepatide treatment on fat distribution in patients...
Obsidian Therapeutics Study Finds Hope in Advanced Melanoma
Obsidian Therapeutics, a biotechnology company, unveiled promising updates on its Phase 1 study of OBX-115, a tumor-infiltrating lymphocyte (TIL)...